AKT1 and osteosarcoma: Epidermal growth factor (EGF) promotes cell epithelial-mesenchymal transition, metastasis, and progression of osteosarcoma by activating MAPK and PI3K/AKT pathway, which can be blocked by the EGFR-specific inhibitor gefitinib [52].